← All trials
NCT00609401
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2006
- Primary completion
- May 1, 2007
- Completion date
- May 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Italian Trial in Medical OncologyLead sponsor
- Azienda Ospedaliera San Gerardo di MonzaStudy director
- University of BresciaStudy director
- University of PisaStudy director
- Ospedale di MantovaStudy director
- A.O. Melegnano - GorgonzolaStudy director
- Ospedale di ComoStudy director
- Ospedaliera ValtellinaStudy director
- Vita-Salute University of Milano. ItalyStudy director
- University of TurinStudy director
- University of UdineStudy director
- University of PaviaStudy director
- University of SienaStudy director
- University of PerugiaStudy director
- University of PadovaStudy director
- Marche Polytechnic UniversityStudy director
- Ospedale Fatebenefratelli di RomaStudy director
- University of MilanOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.